{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T01:26:50Z","timestamp":1776389210895,"version":"3.51.2"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.dmpk.2016.11.007","type":"journal-article","created":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T21:00:14Z","timestamp":1479502814000},"page":"135-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Quantitative prediction of histamine H1 receptor occupancy by the sedative and non-sedative antagonists in the human central nervous system based on systemic exposure and preclinical data"],"prefix":"10.1016","volume":"32","author":[{"given":"Kayoko","family":"Kanamitsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitane","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Nagaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Kusuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmpk.2016.11.007_bib1","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJM199406093302307","article-title":"The pharmacology and use of H1-receptor-antagonist drugs","volume":"330","author":"Simons","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dmpk.2016.11.007_bib2","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/j.1476-5381.1995.tb16386.x","article-title":"Histamine H1 receptor occupancy in human brains after single oral doses of histamine H1 antagonists measured by positron emission tomography","volume":"116","author":"Yanai","year":"1995","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.dmpk.2016.11.007_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2006.06.008","article-title":"The physiological and pathophysiological roles of neuronal histamine: an insight from human positron emission tomography studies","volume":"113","author":"Yanai","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2016.11.007_bib4","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1046\/j.1365-2125.2001.01471.x","article-title":"Neuroimaging of histamine H1-receptor occupancy in human brain by positron emission tomography (PET): a comparative study of ebastine, a second-generation antihistamine, and (+)-chlorpheniramine, a classical antihistamine","volume":"52","author":"Tagawa","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2016.11.007_bib5","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1046\/j.0306-5251.2001.01183.x","article-title":"Differential cognitive effects of ebastine and (+)-chlorpheniramine in healthy subjects: correlation between cognitive impairment and plasma drug concentration","volume":"53","author":"Tagawa","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2016.11.007_bib6","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1177\/0091270004267590","article-title":"Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography","volume":"44","author":"Tashiro","year":"2004","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2016.11.007_bib7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2125.2005.02514.x","article-title":"Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen","volume":"61","author":"Tashiro","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2016.11.007_bib8","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1365-2125.2008.03143.x","article-title":"Brain histamine H1 receptor occupancy of orally administered antihistamines, bepotastine and diphenhydramine, measured by PET with 11C-doxepin","volume":"65","author":"Tashiro","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2016.11.007_bib9","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/JCP.0b013e3181fa8526","article-title":"Next-day residual sedative effect after nighttime administration of an over-the-counter antihistamine sleep aid, diphenhydramine, measured by positron emission tomography","volume":"30","author":"Zhang","year":"2010","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.dmpk.2016.11.007_bib10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1471-4159.1990.tb04152.x","article-title":"Specific binding of [3H]pyrilamine to histamine H1 receptors in Guinea pig brain in\u00a0vivo: determination of binding parameters by a kinetic four-compartment model","volume":"55","author":"Yanai","year":"1990","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.dmpk.2016.11.007_bib11","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1124\/dmd.108.022814","article-title":"Receptor occupancy and brain free fraction","volume":"37","author":"Watson","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2016.11.007_bib12","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.dmpk.2016.07.003","article-title":"Prediction of CNS occupancy of dopamine D2 receptor based on systemic exposure and in\u00a0vitro experiments","volume":"31","author":"Kanamitsu","year":"2016","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.dmpk.2016.11.007_bib13","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1124\/dmd.105.007559","article-title":"Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate","volume":"34","author":"Ohashi","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2016.11.007_bib14","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2133\/dmpk.23.106","article-title":"P-glycoprotein limits the brain penetration of olopatadine hydrochloride, H1-receptor antagonist","volume":"23","author":"Mimura","year":"2008","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.dmpk.2016.11.007_bib15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/2045-8118-10-8","article-title":"Functional expression of a proton-coupled organic cation (H+\/OC) antiporter in human brain capillary endothelial cell line hCMEC\/D3, a human blood-brain barrier model","volume":"10","author":"Shimomura","year":"2013","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.dmpk.2016.11.007_bib16","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1002\/jps.22567","article-title":"Diphenhydramine active uptake at the blood-brain barrier and its interaction with oxycodone in\u00a0vitro and in\u00a0vivo","volume":"100","author":"Sadiq","year":"2011","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.dmpk.2016.11.007_bib17","first-page":"355","article-title":"Histamine-induced calcium mobilization in single cultured cells expressing histamine H1 receptors: a relationship between its sensitivity and the density of H1 receptors","volume":"1","author":"Ohuchi","year":"1998","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.dmpk.2016.11.007_bib18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ejphar.2005.11.051","article-title":"Changes in pH differently affect the binding properties of histamine H1 receptor antagonists","volume":"530","author":"Gillard","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.dmpk.2016.11.007_bib19","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1248\/bpb1978.4.879","article-title":"A\u00a0pharmacokinetic analysis program (multi) for microcomputer","volume":"4","author":"Yamaoka","year":"1981","journal-title":"J\u00a0Pharmacobiodyn"},{"key":"10.1016\/j.dmpk.2016.11.007_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0026-895X(25)15016-5","article-title":"The kinetics of competitive radioligand binding predicted by the law of mass action","volume":"25","author":"Motulsky","year":"1984","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.dmpk.2016.11.007_bib21","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1124\/dmd.107.015222","article-title":"In\u00a0vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids","volume":"35","author":"Frid\u00e9n","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2016.11.007_bib22","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1124\/jpet.111.180398","volume":"339","author":"Kodaira","year":"2011","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.dmpk.2016.11.007_bib23","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1002\/jps.23600","article-title":"Investigation of the effect of active efflux at the blood-brain barrier on the distribution of nonsteroidal aromatase inhibitors in the central nervous system","volume":"102","author":"Miyajima","year":"2013","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.dmpk.2016.11.007_bib24","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2133\/dmpk.DMPK-14-RG-026","article-title":"Utility of cerebrospinal fluid drug concentration as a surrogate for unbound brain concentration in nonhuman primates","volume":"29","author":"Nagaya","year":"2014","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.dmpk.2016.11.007_bib25","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/jps.21405","article-title":"Ionization-specific prediction of blood-brain permeability","volume":"98","author":"Lanevskij","year":"2009","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.dmpk.2016.11.007_bib26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/bdd.2510110302","article-title":"Diphenhydramine kinetics following intravenous, oral, and sublingual dimenhydrinate administration","volume":"11","author":"Scavone","year":"1990","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.dmpk.2016.11.007_bib27","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1002\/rcm.1189","article-title":"Determination of ketotifen and its conjugated metabolite in human plasma by liquid chromatography\/tandem mass spectrometry: application to a pharmacokinetic study","volume":"17","author":"Chen","year":"2003","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1016\/j.dmpk.2016.11.007_bib28","first-page":"1137","article-title":"Phase I study of TAU-284: single oral administration in healthy male volunteers","volume":"13","author":"Yokota","year":"1997","journal-title":"Rinsho Iyaku"},{"key":"10.1016\/j.dmpk.2016.11.007_bib29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/anatox\/35.2.113","article-title":"A\u00a0rapid and sensitive liquid chromatography-tandem mass spectrometry method for determination of olopatadine concentration in human plasma","volume":"35","author":"Zhu","year":"2011","journal-title":"J\u00a0Anal Toxicol"},{"key":"10.1016\/j.dmpk.2016.11.007_bib30","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0022-3565(25)13107-8","article-title":"Brain efflux index as a novel method of analyzing efflux transport at the blood\u2013brain barrier","volume":"277","author":"Kakee","year":"1996","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.dmpk.2016.11.007_bib31","doi-asserted-by":"crossref","first-page":"6640","DOI":"10.1016\/j.bmc.2006.05.077","article-title":"Novel ligands for the human histamine H1 receptor: synthesis, pharmacology, and comparative molecular field analysis studies of 2-dimethylamino-5-(6)-phenyl-1,2,3,4-tetrahydronaphthalenes","volume":"14","author":"Ghoneim","year":"2006","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.dmpk.2016.11.007_bib32","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/jpet.302.1.328","article-title":"A\u00a0novel phenylaminotetralin radioligand reveals a subpopulation of histamine H(1) receptors","volume":"302","author":"Booth","year":"2002","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.dmpk.2016.11.007_bib33","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1021\/jm00089a020","article-title":"Synthesis and antiallergic activity of 11-(aminoalkylidene)-6,11-dihydrodibenz[b,e]oxepin derivatives","volume":"35","author":"Ohshima","year":"1992","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.dmpk.2016.11.007_bib34","first-page":"1116","article-title":"Pharmacokinetic and pharmacodynamic evaluation of central effect of the novel antiallergic agent betotastine besilate","volume":"47","author":"Kato","year":"1997","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.dmpk.2016.11.007_bib35","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0022-3565(25)20776-5","article-title":"Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases","volume":"278","author":"Sharif","year":"1996","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.dmpk.2016.11.007_bib36","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0014-2999(82)90029-2","article-title":"High-affinity binding of [3H]doxepin to histamine H1-receptors in rat brain: possible identification of a subclass of histamine H1-receptors","volume":"78","author":"Taylor","year":"1982","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.dmpk.2016.11.007_bib37","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2967\/jnumed.108.058537","article-title":"Cerebral histamine H1 receptor binding potential measured with PET under a test dose of olopatadine, an antihistamine, is reduced after repeated administration of olopatadine","volume":"50","author":"Senda","year":"2009","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.dmpk.2016.11.007_bib38","unstructured":"http:\/\/www.kowa-souyaku.co.jp\/upload\/item\/51\/1-pi_128.pdf."},{"key":"10.1016\/j.dmpk.2016.11.007_bib39","unstructured":"https:\/\/medical.mt-pharma.co.jp\/di\/file\/if\/f_zen_a.pdf"},{"key":"10.1016\/j.dmpk.2016.11.007_bib40","unstructured":"https:\/\/medical.mt-pharma.co.jp\/di\/file\/if\/f_tln.pdf."},{"key":"10.1016\/j.dmpk.2016.11.007_bib41","unstructured":"http:\/\/www.kksmile.com\/druginfo\/interv\/alk_in.pdf."},{"key":"10.1016\/j.dmpk.2016.11.007_bib42","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1021\/mp200129p","article-title":"Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels","volume":"8","author":"Shawahna","year":"2011","journal-title":"Mol Pharm"},{"key":"10.1016\/j.dmpk.2016.11.007_bib43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2045-8118-10-21","volume":"10","author":"Uchida","year":"2013","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.dmpk.2016.11.007_bib44","first-page":"1531","article-title":"Quantitative analysis of 11C-verapamil transfer at the human blood-brain barrier for evaluation of P-glycoprotein function","volume":"47","author":"Ikoma","year":"2006","journal-title":"J\u00a0Nucl Med"}],"updated-by":[{"DOI":"10.1016\/j.dmpk.2017.05.003","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000}}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S134743671630550X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S134743671630550X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T19:00:01Z","timestamp":1749754801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S134743671630550X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S134743671630550X"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2016.11.007","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantitative prediction of histamine H1 receptor occupancy by the sedative and non-sedative antagonists in the human central nervous system based on systemic exposure and preclinical data","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2016.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Ltd on behalf of The Japanese Society for the Study of Xenobiotics.","name":"copyright","label":"Copyright"}]}}